Cargando…
Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study
Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 year. The first 43 patients had an initial follow-up...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057553/ https://www.ncbi.nlm.nih.gov/pubmed/36992077 http://dx.doi.org/10.3390/vaccines11030493 |
_version_ | 1785016396988547072 |
---|---|
author | Rossi, Jean-François Bonnet, Emmanuel Castelli, Christel Velensek, Marion Wisniewski, Emma Heraud, Sophie Boustany, Rania David, Céleste Dinet, Jérôme Sicard, Roland Daures, Jean-Pierre Bonifacy, Marion Mousset, Lysiane Goffart, Emmanuel |
author_facet | Rossi, Jean-François Bonnet, Emmanuel Castelli, Christel Velensek, Marion Wisniewski, Emma Heraud, Sophie Boustany, Rania David, Céleste Dinet, Jérôme Sicard, Roland Daures, Jean-Pierre Bonifacy, Marion Mousset, Lysiane Goffart, Emmanuel |
author_sort | Rossi, Jean-François |
collection | PubMed |
description | Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 year. The first 43 patients had an initial follow-up by a telemedicine (TM) system with no major events reported. The anti-spike IgG antibodies were checked 3–4 weeks post-first vaccination and every 3–4 months, by two standard bioassays and a rapid serological test (RST). Vaccine boosts were given when the level was <7 BAU/mL. Patients who did not seroconvert after 3–4 doses received tixagevimab/cilgavimab (TC). Fifteen results were discordant between two standard bioassays. Good agreement was observed between the standard and RST in 97 samples. After two doses, 68% were seroconverted (median = 59 BAU/mL) with a median of 162 BAU/mL and 9 BAU/mL, respectively, in untreated and treated patients (p < 0.001), particularly for patients receiving rituximab. Patients with gammaglobulin levels < 5 g/L had reduced seroconversion compared to higher levels (p = 0.019). The median levels were 228 BAU/mL post-second dose if seroconverted post-first and second, or if seroconverted only post-second dose. A total of 68% of post-second dose negative patients were post-third dose positive. A total of 16% received TC, six with non-severe symptomatic COVID-19 within 15–40 days. Personalized serological follow-up should apply particularly to patients with HMs. |
format | Online Article Text |
id | pubmed-10057553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100575532023-03-30 Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study Rossi, Jean-François Bonnet, Emmanuel Castelli, Christel Velensek, Marion Wisniewski, Emma Heraud, Sophie Boustany, Rania David, Céleste Dinet, Jérôme Sicard, Roland Daures, Jean-Pierre Bonifacy, Marion Mousset, Lysiane Goffart, Emmanuel Vaccines (Basel) Article Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 year. The first 43 patients had an initial follow-up by a telemedicine (TM) system with no major events reported. The anti-spike IgG antibodies were checked 3–4 weeks post-first vaccination and every 3–4 months, by two standard bioassays and a rapid serological test (RST). Vaccine boosts were given when the level was <7 BAU/mL. Patients who did not seroconvert after 3–4 doses received tixagevimab/cilgavimab (TC). Fifteen results were discordant between two standard bioassays. Good agreement was observed between the standard and RST in 97 samples. After two doses, 68% were seroconverted (median = 59 BAU/mL) with a median of 162 BAU/mL and 9 BAU/mL, respectively, in untreated and treated patients (p < 0.001), particularly for patients receiving rituximab. Patients with gammaglobulin levels < 5 g/L had reduced seroconversion compared to higher levels (p = 0.019). The median levels were 228 BAU/mL post-second dose if seroconverted post-first and second, or if seroconverted only post-second dose. A total of 68% of post-second dose negative patients were post-third dose positive. A total of 16% received TC, six with non-severe symptomatic COVID-19 within 15–40 days. Personalized serological follow-up should apply particularly to patients with HMs. MDPI 2023-02-21 /pmc/articles/PMC10057553/ /pubmed/36992077 http://dx.doi.org/10.3390/vaccines11030493 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rossi, Jean-François Bonnet, Emmanuel Castelli, Christel Velensek, Marion Wisniewski, Emma Heraud, Sophie Boustany, Rania David, Céleste Dinet, Jérôme Sicard, Roland Daures, Jean-Pierre Bonifacy, Marion Mousset, Lysiane Goffart, Emmanuel Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study |
title | Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study |
title_full | Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study |
title_fullStr | Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study |
title_full_unstemmed | Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study |
title_short | Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study |
title_sort | clinical and serological follow-up of 216 patients with hematological malignancies after vaccination with pfizer-biont162b2 mrna covid-19 in a real-world study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057553/ https://www.ncbi.nlm.nih.gov/pubmed/36992077 http://dx.doi.org/10.3390/vaccines11030493 |
work_keys_str_mv | AT rossijeanfrancois clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT bonnetemmanuel clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT castellichristel clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT velensekmarion clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT wisniewskiemma clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT heraudsophie clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT boustanyrania clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT davidceleste clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT dinetjerome clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT sicardroland clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT dauresjeanpierre clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT bonifacymarion clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT moussetlysiane clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy AT goffartemmanuel clinicalandserologicalfollowupof216patientswithhematologicalmalignanciesaftervaccinationwithpfizerbiont162b2mrnacovid19inarealworldstudy |